Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels

Annals of Internal Medicine

Volumn 139, Issue 11, 2003, Pages E959-

  Brillanti, Stefano ^a   Levantesi, Fabio ^a   Nigro, Giovanni ^a   Vicari, Susanna ^a   Roda, Enrico ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; PEGINTERFERON; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ALANINE AMINOTRANSFERASE LEVEL; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; BLOOD; DRUG COMBINATION; ENZYMOLOGY; FEMALE; HEPATITIS C; MALE; MIDDLE AGED;

ALANINE TRANSAMINASE; AMANTADINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 0642346342     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-139-11-200312020-00022-w2     Document Type: Letter

References (4)

1. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 2000;118:760-4. [PMID: 10734027]
2. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology. 2002;36:S179-84. [PMID: 12407592]
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82. [PMID: 12324553]
4. Brillanti S, Mangia A, Cimino L, Civolani A, Fatuzzo F, Fenoglio L, et al. Re-treatment of interferon plus ribavirin non-responders with peginterferon alfa-2a (40 Kda) plus ribavirin and amantadine or interferon alfa-2a plus ribavirin and amantadine. Interim results of a multicenter randomized study [Abstract]. J Hepatol. 2003; 38(S2):129.